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Zika virus (ZIKV) is an emerging arthropod-borne virus
(arbovirus) belonging to the family Flaviviridae and genus
Flavivirus. ZIKV was ﬁrst isolated from a monkey in the Zika
forest of Uganda in 1947 [1].
Subsequently, sporadic human infections were reported
in Africa and Asia. In 2007, the ﬁrst large documented
ZIKV outbreak was reported from Yap State, Federated
States of Micronesia [2]. No further transmission was
identiﬁed in the Paciﬁc until October 2013, when French
Polynesia (FP) reported the ﬁrst cases; a subsequent
explosive outbreak resulted in an estimated 28 000 cases
seeking medical care (approximately 11% of the population)
[3,4].
Phylogenetic analyses demonstrated that the FP strain was
closely related to Cambodia 2010 and Yap State 2007 strains,
corroborating previous ﬁndings of the expansion of the ZIKV
Asian lineage [3].
During the FP outbreak, most clinical cases presented with
mild disease characterized by low-grade fever, maculopapular
rash, arthralgia, and conjunctivitis.
In November, a patient presented with Guillain–Barre
syndrome (GBS), an autoimmune disease causing acute or
subacute ﬂaccid paralysis, 1 week after a conﬁrmed acute
ZIKV infection [5]. Subsequent GBS cases were identiﬁed,
correlating temporally with the ZIKV outbreak. The incidence
rate of GBS cases during the ZIKV outbreak was approxi-
mately 20-fold higher than expected given the size of the FP
population and the established incidence rates of GBS (1–2/
100 000 population per year) [6].
No severe disease resulting from ZIKV infection had been
reported prior to the FP outbreak, but previous clinical
characterization was based on a limited number of conﬁrmed
cases. The recent temporal and spatial association between the
FP ZIKV outbreak and the highly unusual GBS cluster is very
FIG. 1. Circulation of Zika virus in the Paciﬁc: FSM (Federated States of Micronesia, 2007), FP (French Polynesia, 2013/2014), NC (New Caledonia,
2014), CI (Cook Islands, 2014), EI (Ester Island, 2014).
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suspicious, but does not conﬁrm ZIKV as the antigenic
stimulus predisposing to this autoimmune disease.
ZIKV is transmitted by the bite of infected mosquitoes, and
has been isolated from several Aedes mosquito species [7],
notably Aedes aegypti, which is widespread in the tropics and
subtropics, and Aedes albopictus, which is established in many
parts of Europe, especially in Mediterranean countries. In FP,
Aedes polynesiensis is also suspected to contribute to ZIKV
transmission.
Non-vector borne ZIKV transmission through sexual
intercourse [8] and perinatal transmission [4] has been
reported. Given that transfusion-related ZIKV transmission is
a potential risk, molecular screening was implemented in FP
for blood donors during the outbreak: 2.8% of blood donors,
who were asymptomatic at the time of donation, tested
positive for acute ZIKV infection [9].
Following the FP outbreak in late 2013, there were
subsequent outbreaks in New Caledonia, the Cook Islands,
and Easter Island [10] (Fig. 1). Because of the typically mild
clinical symptoms, limited ZIKV diagnostic capacity, and over-
lapping clinical features of ZIKV, dengue, and chikungunya, which
are also circulating in the Paciﬁc, we believe that ongoing and
undetected ZIKV transmission in other Paciﬁc island countries,
and potentially beyond, is highly probable. The observation that
severe clinical complications may occur highlights the need to
strengthen surveillance for this emerging virus, and, in the event
of a ZIKV outbreak, establish rigorous clinical monitoring to
detect GBS or other unusual clinical manifestations.
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